(Q44557805)

4 December 2017

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia (English)

1 reference

4 December 2017

0 references

8

Keith M Sullivan

1 reference

4 December 2017

9

Rainer F Storb

1 reference

4 December 2017

6

Ann Woolfrey

1 reference

4 December 2017

Robert Iannone

1

1 reference

4 December 2017

James F Casella

2

1 reference

4 December 2017

Ephraim J Fuchs

3

1 reference

4 December 2017

Allen R Chen

4

1 reference

4 December 2017

Richard J Jones

5

1 reference

4 December 2017

Michael Amylon

7

1 reference

4 December 2017

Mark C Walters

10

1 reference

4 December 2017

1 August 2003

1 reference

Biology of Blood and Marrow Transplantation

4 December 2017

1 reference

4 December 2017

9

1 reference

4 December 2017

519-528

1 reference

4 December 2017

8

1 reference

Bone marrow transplantation for sickle cell disease: where do we go from here?

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Bone marrow transplantation for sickle cell disease. A study of parents' decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Fluorescence in situ hybridization to determine engraftment status after murine bone marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Bone marrow transplantation without myeloablation for sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900192-7

7 January 2021

10.1016/S1083-8791(03)00192-7

Identifiers

DOI

1 reference

4 December 2017

1 reference